Bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis

Bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis - Combination therapy of calcipotriene and nicotinamide for psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004584

Enrollment

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

Apply 0.005%calcipotriene ointment containing 1.4% niconinamide to an indicated skin lesion twice daily everyday.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with psoriasis who visit our out-patient clinic and meet the following criteria; 1) Patients under moderate severity treated with topical therapy alone 2) Patients treated with combination therapy of ultraviolet and topical therapy 3) Patients treated with systemic therapy and topical therapy

Exclusion criteria

Exclusion criteria: Patients treated with anti TNF antibodies and patients who experienced worsening of psoriasis treated with calcipotriene will be excluded.

Design outcomes

Primary

Measure	Time frame
We evaluate therapeutic response according to the PASI (psoriasis area and severity index).	—

Secondary

Measure	Time frame
We evaluate the severity of skin lesion by calculating the score of erythema, infiltration and scale of the skin lesion.	—

Countries

Japan

Contacts

Public ContactWataru Fujimoto

Kawasaki Medical School Department of Dermatology

watarufu@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026